Does DSIP need a reducing agent?

No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.

Why protect DSIP from light if it has no methionine?

Its single tryptophan is mildly photosensitive. It is a weaker liability than methionine oxidation but it is the one this sequence has.

Why might DSIP dissolve unevenly?

It is strongly acidic with no basic residue, and solubility of a charged peptide is pH-dependent. The diluent's pH is a real variable.

DSIP Storage, Stability and Reconstitution

The short answer

DSIP is supplied lyophilised and is most stable in that state, stored cold, dry and protected from light. It has neither cysteine nor methionine, so disulfide chemistry and methionine oxidation do not apply. Its strongly acidic character is the main variable affecting solubility.

Key facts

Supplied as: White lyophilised powder
Disulfide risk: None (no cysteine)
Methionine oxidation: Not applicable (none present)
Main route: Hydrolysis
Charge: Strongly negative at physiological pH
Light: Single tryptophan is mildly photosensitive
Freeze-thaw: Avoid by aliquoting

Why lyophilised is the stable state

Water participates in peptide-bond hydrolysis, so removing it removes the principal degradation route. A dry powder held cold has limited chemistry available to it. This applies to research peptides generally, and it is why the condition of material on arrival matters. A warm transit is time spent in a less protected state.

What does not apply here

Most peptide handling guidance addresses two liabilities. Cysteine forms and scrambles disulfide bonds; methionine oxidises to the sulfoxide, adding 16 Da. DSIP has neither residue. That removes the two most commonly discussed failure modes and makes it, chemically, one of the more forgiving research peptides.

Research material referenced

DSIP 5mg, third-party HPLC tested

Buy DSIP · £13.99

The tryptophan is the reason to keep it dark

Tryptophan at position 1 is mildly photosensitive and can degrade under prolonged light exposure. This is a weaker liability than methionine oxidation but it is the one DSIP actually has, and it is a specific reason to protect solutions from light rather than a generic instruction.

Charge and solubility

With aspartate and glutamate and no basic residue, DSIP is strongly negatively charged at physiological pH. Solubility of a charged peptide is pH-dependent and drops near its isoelectric point, which for an acidic peptide sits low. Behaviour in bacteriostatic water at pH 5.7 may therefore differ noticeably from behaviour in a neutral buffer. Worth knowing if a preparation dissolves less readily than expected.

Reconstitution

Bacteriostatic water is the usual diluent for research peptides, its benzyl alcohol permitting repeated entry over a limited window. Introduce solvent gently against the vial wall rather than onto the powder, and swirl rather than shake. Peptides denature at air-liquid interfaces, and foaming is the visible sign that one has been created.

After reconstitution

Solution-phase material is subject to hydrolysis and is markedly less stable than the lyophilised powder. Aliquot into single-use volumes rather than freeze-thawing repeatedly; each cycle concentrates solutes at the advancing ice boundary and creates further interfaces. Cloudiness, particulates or discolouration mean the material should not be relied on for a measurement.

Frequently asked questions

Does DSIP need a reducing agent?: No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.
Why protect DSIP from light if it has no methionine?: Its single tryptophan is mildly photosensitive. It is a weaker liability than methionine oxidation but it is the one this sequence has.
Why might DSIP dissolve unevenly?: It is strongly acidic with no basic residue, and solubility of a charged peptide is pH-dependent. The diluent's pH is a real variable.

Extended research context

The DSIP (Delta Sleep-Inducing Peptide) deep dive

Deep dive: a name that was a hypothesis, not a finding

In 1977 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected blood draining from its brain, isolated a peptide fraction, and reported that administering it into the ventricles of awake rabbits produced delta-wave EEG activity. They named it delta sleep-inducing peptide. By the standards of the time this was careful, imaginative work, and they followed it properly: the 1978 Pflugers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide rather than stopping at a suggestive fraction. The problem is not the original research. It is that a name recording a hypothesis has been read ever since as a summary of established pharmacology, and almost nobody checks whether it was earned.

Deep dive: the three things that are missing

A proposed endogenous peptide becomes accepted biology by a recognisable route. The gene is located. The precursor protein is characterised. A receptor is identified, giving a mechanism and a testable target. DSIP has completed none of these in nearly fifty years. The receptor gap is the most disabling. Without one there is no mechanism to test, no dose-response to build, no antagonist to design, and no way to establish that an observed effect runs through the proposed pathway at all. The gene gap is the hardest to explain away: modern genomics located MOTS-c inside a short open reading frame nested within the mitochondrial 12S rRNA gene, sequence already annotated as something else. That a peptide described in 1977 still has no identified gene in any genome is a substantive observation, not an accident of effort.

Deep dive: why 519 papers is not 519 confirmations

DSIP has roughly 519 indexed PubMed records, more than Selank's 135 or Semax's 231. Publication volume tracks how interesting a question is, not how well it has been answered. A tractable question generates a burst of work and then stops; a question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. Kovalzon's 2006 review in the Journal of Neurochemistry states the field's own assessment in its title: a still unresolved riddle. Reading any individual DSIP paper without that context invites mistaking activity for consensus.

Research applications

▸Historical study of humoral sleep-factor hypotheses
▸Electroencephalography and delta-wave research methodology
▸Structure-activity work on flexible, acidic short peptides
▸Comparative work on peptides lacking identified receptors
▸Analytical method development for tryptophan-containing peptides

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed, as the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Protect from prolonged light, as the single tryptophan is mildly photosensitive
✓Expect pH-dependent solubility; the peptide is strongly acidic with no basic residue
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating the name as evidence of the effect

Fix: The name records a 1977 hypothesis from a single rabbit EEG study. It is not a summary of established pharmacology.

✗ Citing the 1977 paper as proof DSIP induces sleep

Fix: It reports delta-wave EEG activity in rabbits after intraventricular administration. That is a narrower claim than inducing sleep, in one species, by a route that bypasses every normal barrier.

✗ Assuming DSIP is an established endogenous human peptide

Fix: No gene has been identified in any species, no precursor characterised and no receptor found.

✗ Reading 519 papers as 519 confirmations

Fix: Volume reflects an unresolved question attracting sustained attempts, not accumulated confirmation.

✗ Making any sleep claim about supplied material

Fix: The evidence does not support it and a therapeutic claim about research material is what MHRA enforcement targets.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More DSIP (Delta Sleep-Inducing Peptide) articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum